21ENGBIO Controllable DNA polycatenanes of infinite length for intelligent biomaterials

21ENGBIO 用于智能生物材料的无限长度可控 DNA 聚链烷

基本信息

  • 批准号:
    BB/W01338X/1
  • 负责人:
  • 金额:
    $ 12.85万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2022
  • 资助国家:
    英国
  • 起止时间:
    2022 至 无数据
  • 项目状态:
    已结题

项目摘要

DNA is an ideal substrate from which to construct new materials for medical applications because it is sustainable, biodegradable, biocompatible, non-toxic, and highly programmable. DNA hydrogels have state-of-the-art applications in regenerative therapy (like stimulating new tissue growth from stem cells) and biologics delivery (like controlled, sustained release of insulin). They are squishy, gel-like materials made of water and web-like structures of DNA, and they can obtain unique properties when combined with nanomaterials. The disadvantages of current DNA hydrogels are in how their web-like structures of DNA are held together. Many rely on the ability of compatible DNA strands to stick together but this stickiness is susceptible changes in environmental conditions such as an increase in temperature which causes the structures to unravel. Adding small molecules to reinforce the DNA structures through cross-linking increases the manufacturing time and cost. Here, we will synthesise never-before-made DNA-based materials from polycatenanes. Polycatenanes are polymers in which molecular rings are mechanically linked together akin to the links of a chain. We have devised a strategy to make DNA polycatenanes of infinite and controllable lengths using enzymes to connect rings of DNA. In addition to enabling assembly 1D DNA chains, our strategy will enable construction of 2D and 3D DNA structures that require no cross-linking small molecules and will not unravel upon changes in environmental conditions. This work aims to seed development of a new family of structurally unique DNA-based biomaterials for programmable biologics delivery and patient-specific regenerative therapies.
DNA是构建医学应用新材料的理想底物,因为它具有可持续性、可生物降解、生物相容性、无毒和高度可编程性。DNA水凝胶在再生治疗(如刺激干细胞的新组织生长)和生物制剂输送(如控制胰岛素的持续释放)方面有着最先进的应用。它们是由水和网状DNA结构组成的柔软的凝胶状材料,当与纳米材料结合时,它们可以获得独特的性能。目前DNA水凝胶的缺点在于它们的网状DNA结构是如何结合在一起的。许多人依靠兼容的DNA链粘在一起的能力,但这种粘在一起的能力很容易受到环境条件变化的影响,比如温度升高,这会导致结构解体。添加小分子通过交联来增强DNA结构增加了制造时间和成本。在这里,我们将从聚连环烷合成前所未有的dna基材料。聚连环烷是一种聚合物,其分子环机械地连接在一起,类似于链的链接。我们已经设计出一种策略,利用酶连接DNA环,制造出无限和可控长度的DNA聚连环烷。除了能够组装1D DNA链外,我们的策略还将能够构建不需要交联小分子的2D和3D DNA结构,并且在环境条件变化时不会解开。这项工作旨在为可编程生物制剂输送和患者特异性再生治疗提供一种结构独特的基于dna的新生物材料家族。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Susan Rosser其他文献

Synthetic biology approaches for dynamic CHO cell engineering
  • DOI:
    10.1016/j.copbio.2022.102806
  • 发表时间:
    2022-12-01
  • 期刊:
  • 影响因子:
    7.000
  • 作者:
    James Donaldson;Dirk-Jan Kleinjan;Susan Rosser
  • 通讯作者:
    Susan Rosser

Susan Rosser的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Susan Rosser', 18)}}的其他基金

Engineered Genetic Control Systems for Advanced Therapeutics
用于先进治疗的工程基因控制系统
  • 批准号:
    BB/Y008545/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
21EBTA Engineering Biology for Cell and Gene Therapy Applications
21EBTA 细胞和基因治疗应用工程生物学
  • 批准号:
    BB/W014610/1
  • 财政年份:
    2022
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
Optimisation of CHO for Biotherapeutic Manufacture
生物治疗药物生产中 CHO 的优化
  • 批准号:
    EP/V038095/1
  • 财政年份:
    2021
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
A Novel Single Subunit RNA Polymerases for Commercial RNA Manufacturing
用于商业 RNA 生产的新型单亚基 RNA 聚合酶
  • 批准号:
    BB/T017236/1
  • 财政年份:
    2020
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
Harnessing enzymes from plants for selective functionalisation of triterpenoid scaffolds
利用植物酶选择性功能化三萜类支架
  • 批准号:
    BB/S017712/1
  • 财政年份:
    2019
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
University of Edinburgh ROSSER UKRI Innovation Fellowships: BBSRC Flexible Talent Mobility Accounts
爱丁堡大学 ROSSER UKRI 创新奖学金:BBSRC 灵活人才流动账户
  • 批准号:
    BB/R506606/1
  • 财政年份:
    2017
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
A Combinatorial Approach to Enhance Production of Monoclonal Antibodies
提高单克隆抗体产量的组合方法
  • 批准号:
    BB/M018229/1
  • 财政年份:
    2016
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
Assay Development Platforms
检测开发平台
  • 批准号:
    BB/M025659/1
  • 财政年份:
    2015
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
Industrial Saponins
工业皂苷
  • 批准号:
    BB/M028860/1
  • 财政年份:
    2015
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
SynthSys-Mammalian: Edinburgh Mammalian Synthetic Biology Research Centre
SynthSys-Mammalian:爱丁堡哺乳动物合成生物学研究中心
  • 批准号:
    BB/M018040/1
  • 财政年份:
    2014
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant

相似海外基金

Controllable quantum phases in two-dimensional metal-organic nanomaterials
二维金属有机纳米材料中的可控量子相
  • 批准号:
    DP240102006
  • 财政年份:
    2024
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Discovery Projects
Controllable Cluster Fusion of the Main-Group-Element(E)-Centered Gold(I) Polyhedral Clusters and Creation of Composite Optical Functions
主族元素(E)中心金(I)多面体团簇的可控团簇聚变及复合光学函数的创建
  • 批准号:
    24K08443
  • 财政年份:
    2024
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Controllable generation for instruction-following language models
职业:指令跟随语言模型的可控生成
  • 批准号:
    2338866
  • 财政年份:
    2024
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Continuing Grant
21ENGBIO A Universal and Controllable Interface between Synthetic Cells and Living Cells
21ENGBIO 合成细胞和活细胞之间的通用且可控的接口
  • 批准号:
    BB/W011468/1
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Research Grant
CAREER: Timeliness as a Controllable Dimension via Knowledge-driven System Management
职业:通过知识驱动的系统管理将及时性作为可控维度
  • 批准号:
    2238476
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Continuing Grant
LEAPS-MPS: Controllable sets for nonlinear switched models with applications to infectious diseases
LEAPS-MPS:非线性切换模型的可控集及其在传染病中的应用
  • 批准号:
    2315862
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Standard Grant
4D controllable extracellular matrix properties to guide iPSC-derived intestinal organoid fate and form
4D 可控细胞外基质特性指导 iPSC 衍生的肠道类器官的命运和形成
  • 批准号:
    10644759
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
User-controllable and Physics-informed Neural Acoustics Fields for Multichannel Audio Rendering and Analysis in Mixed Reality Application
用于混合现实应用中多通道音频渲染和分析的用户可控且基于物理的神经声学场
  • 批准号:
    23K16913
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
RI: Small: Integrating physics, data, and art-based insights for controllable generative models
RI:小型:集成物理、数据和基于艺术的见解以实现可控生成模型
  • 批准号:
    2323086
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
    Standard Grant
Co-Delivery Dose-Controllable Implants for Advanced Chronic Eye Disease Treatment
用于治疗晚期慢性眼病的共同给药剂量可控植入物
  • 批准号:
    10647078
  • 财政年份:
    2023
  • 资助金额:
    $ 12.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了